Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials

Bibliography

• Thase ME, Sloan DM, Kornstein SG. Remission as the critical outcome of depression treatment. Psychopharmacol Bull 2002;36(4 Suppl 3):12-25
   PubMedGoogle Scholar
• Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003;289:3152-60
   PubMed Web of Science ®Google Scholar
• Von Korff M, Katon W, Unutzer J, Improving depression care: barriers, solutions, and research needs. J Fam Pract 2001;50:E1
   PubMedGoogle Scholar
• McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004;49(3 Suppl 1):10S-6S
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol 2006;26:600-9
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-63
   PubMed Web of Science ®Google Scholar
• Dube S, Tollefson GD, Thase ME, Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007;9:618-27
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A, Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-19
   PubMed Web of Science ®Google Scholar
• El-Khalili N, Banov M, Bortnick B, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder (MDD): a randomized, placebo-controlled clinical trial (Study 003), 2008 (unpublished)
   Google Scholar
• Weisler R, Joyce M, McGill L, ; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313
   PubMed Web of Science ®Google Scholar
• Cutler A, Montgomery S, Feifel D, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
   PubMed Web of Science ®Google Scholar
• Earley W, McIntyre A, Wang G, Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD), 2008 (unpublished)
   Google Scholar
• Katila H, Mezhebovsky I, Mulroy A, Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD), 2008 (unpublished)
   Google Scholar
• Bauer M, Pretorius HW, Constant E, Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9. [Epub 7 Apr 2009]
   PubMed Web of Science ®Google Scholar
• El-Khalili N, Joyce M, Atkinson S, Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response, 2008 (unpublished)
   Google Scholar
• Datto C, Lam RW, Lepola U, Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD), 2008 (unpublished)
   Google Scholar
• Jensen NH, Rodriguiz RM, Caron MG, N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
   PubMed Web of Science ®Google Scholar
• Winter HR, Earley WR, Hamer-Maansson JE, Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008;18:81-98
   PubMed Web of Science ®Google Scholar
• Nyberg S, Takano A, Grimm S, PET-measured D2, 5HT2A, and NET occupancy by quetiapine and norquetiapine in non-human primates, 2008 (unpublished)
   Google Scholar
• Nyberg S, Takano A, Jucaite A, PET-measured occupancy of the norepinephrine transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects, 2008 (unpublished)
   Google Scholar
• Marcus RN, McQuade RD, Carson WH, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65
   PubMed Web of Science ®Google Scholar